Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy | Zendy

Howard I. Scher | Zendy; Karim Fizazi | Zendy; Fred Saad | Zendy; MaryEllen Taplin | Zendy; Cora N. Sternberg | Zendy; Kurt Miller | Zendy; Ronald de Wit | Zendy; Peter F.A. Mulders | Zendy; Kim N. | Zendy; Neal D. Shore | Zendy; Andrew J. Armstrong | Zendy; Thomas W. Flaig | Zendy; Aude Fléchon | Zendy; Paul N. Mainwaring | Zendy; Mark T. Fleming | Zendy; John D. Hainsworth | Zendy; Mohammad Hirmand | Zendy; Bryan Selby | Zendy; Lynn Seely | Zendy; Johann S. de Bono | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Author(s) -

Howard I. Scher,

Karim Fizazi,

Fred Saad,

MaryEllen Taplin,

Cora N. Sternberg,

Kurt Miller,

Ronald de Wit,

Peter F.A. Mulders,

Kim N.,

Neal D. Shore,

Andrew J. Armstrong,

Thomas W. Flaig,

Aude Fléchon,

Paul N. Mainwaring,

Mark T. Fleming,

John D. Hainsworth,

Mohammad Hirmand,

Bryan Selby,

Lynn Seely,

Johann S. de Bono

Publication year - 2012

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1207506

Subject(s) - enzalutamide , prostate cancer , medicine , androgen receptor , oncology , overall survival , chemotherapy , cancer

Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth. We aimed to evaluate whether enzalutamide prolongs survival in men with castration-resistant prostate cancer after chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research